UBS Group’s Applied Genetic Technologies Corporation AGTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-58,766
| Closed | -$16K | – | 11777 |
|
|
2022
Q3 | $16K | Buy |
58,766
+46,971
| +398% | +$20.5K | ﹤0.01% | 7766 |
|
|
2022
Q2 | $9K | Buy |
+11,795
| New | +$10.5K | ﹤0.01% | 8247 |
|
|
2021
Q3 | – | Sell |
-1,671
| Closed | -$7K | – | 10475 |
|
|
2021
Q2 | $7K | Sell |
1,671
-8,495
| -84% | -$35.2K | ﹤0.01% | 8387 |
|
|
2021
Q1 | $52K | Buy |
10,166
+4,842
| +91% | +$25.1K | ﹤0.01% | 6508 |
|
|
2020
Q4 | $22K | Buy |
5,324
+5,282
| +12,576% | +$25.9K | ﹤0.01% | 6892 |
|
|
2020
Q3 | $0 | Sell |
42
-7,405
| -99% | -$40.4K | ﹤0.01% | 8609 |
|
|
2020
Q2 | $41K | Buy |
7,447
+5,206
| +232% | +$23.8K | ﹤0.01% | 6047 |
|
|
2020
Q1 | $7K | Buy |
2,241
+1,767
| +373% | +$9.31K | ﹤0.01% | 7182 |
|
|
2019
Q4 | $2K | Sell |
474
-3,625
| -88% | -$11.5K | ﹤0.01% | 7884 |
|
|
2019
Q3 | $17K | Sell |
4,099
-13,161
| -76% | -$47.5K | ﹤0.01% | 6843 |
|
|
2019
Q2 | $65K | Sell |
17,260
-2,840
| -14% | -$11.6K | ﹤0.01% | 5695 |
|
|
2019
Q1 | $84K | Sell |
20,100
-1,775
| -8% | -$6.2K | ﹤0.01% | 5201 |
|
|
2018
Q4 | $54K | Buy |
+21,875
| New | +$128K | ﹤0.01% | 6027 |
|
|
2018
Q3 | – | Sell |
-369
| Closed | -$1K | – | 8387 |
|
|
2018
Q2 | $1K | Sell |
369
-2,296
| -86% | -$10.6K | ﹤0.01% | 7866 |
|
|
2018
Q1 | $10K | Sell |
2,665
-10,015
| -79% | -$42.1K | ﹤0.01% | 6895 |
|
|
2017
Q4 | $46K | Buy |
+12,680
| New | +$47.9K | ﹤0.01% | 5909 |
|
|
2017
Q3 | – | Sell |
-31,703
| Closed | -$161K | – | 8105 |
|
|
2017
Q2 | $161K | Buy |
31,703
+30,871
| +3,710% | +$173K | ﹤0.01% | 4877 |
|
|
2017
Q1 | $6K | Sell |
832
-1,521
| -65% | -$11.9K | ﹤0.01% | 6931 |
|
|
2016
Q4 | $22K | Buy |
+2,353
| New | +$21.2K | ﹤0.01% | 6466 |
|
|
2016
Q3 | – | Sell |
-2,490
| Closed | -$35K | – | 8035 |
|
|
2016
Q2 | $35K | Buy |
+2,490
| New | +$38.8K | ﹤0.01% | 5816 |
|
|
2015
Q1 | – | Sell |
-1,449
| Closed | -$30K | – | 9565 |
|
|
2014
Q4 | $30K | Buy |
+1,449
| New | +$29.5K | ﹤0.01% | 7122 |
|
UBS Group's AGTC Position: Q4 2022 in Review
UBS Group sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 58,766 shares — an estimated $16K sold.
UBS Group first reported a position in AGTC in Q4 2014 and held it in 21 quarters. The position peaked at $161K in Q2 2017. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.
- UBS Group reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
- UBS Group sold 58,766 Applied Genetic Technologies Corporation shares in Q4 2022, an estimated $16K.
- UBS Group first reported a position in Applied Genetic Technologies Corporation in Q4 2014 and held it in 21 quarters.
- UBS Group's Applied Genetic Technologies Corporation position peaked at $161K in Q2 2017.
- 0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.
Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.